Kumar SE, Chellaiya GK, Singh KA, Karuppusami R, Daniel D, David VG, et al
There is evidence of androgen excess, altered glucocorticoid regulation and changes in pro-inflammatory cytokines
Hypoglycemia: When used in conjunction with other diabetes medications (like insulin or sulfonylureas), there is an increased risk of low blood sugar (hypoglycemia) due to the combined effects of these drugs
When combined with diet and physical activity changes, brand-name Wegovy is approved by the Food and Drug Administration (FDA) for the following purposes: Weight loss in patients 12 years or older with obesity Body weight reduction in adults who are overweight and have at least one weight-related condition, such as high blood pressure, obstructive sleep apnea (OSA), or Type 2 diabetes Cardiovascular risk reduction in adults with heart disease and either obesity or overweight Treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis Wegovy is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist)
GLP-1 microdosing allows these patients to access the metabolic benefits while minimizing gastrointestinal discomfort, fatigue, or other adverse reactions
